Cargando…
Treating patients with low high-density lipoprotein cholesterol: choices, issues and opportunities
Three clinical trials have recently focused on the benefits of lipid-regulating therapy in populations with normocholesterolaemia and low high-density lipoprotein (HDL)-cholesterol. Two secondary prevention studies (Veterans Affairs HDL-Cholesterol Intervention Trial [VA-HIT] and Bezafibrate Infarct...
Autor principal: | |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2001
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC59631/ https://www.ncbi.nlm.nih.gov/pubmed/11806784 http://dx.doi.org/10.1186/cvm-2-3-118 |
_version_ | 1782120089809584128 |
---|---|
author | Watts, Gerald F |
author_facet | Watts, Gerald F |
author_sort | Watts, Gerald F |
collection | PubMed |
description | Three clinical trials have recently focused on the benefits of lipid-regulating therapy in populations with normocholesterolaemia and low high-density lipoprotein (HDL)-cholesterol. Two secondary prevention studies (Veterans Affairs HDL-Cholesterol Intervention Trial [VA-HIT] and Bezafibrate Infarction Prevention [BIP] trial) testified to the efficacy of fibrates in decreasing cardiovascular events, particularly in patients with coexisting risk factors, including hypertriglyceridaemia. The Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) demonstrated that a statin could decrease acute coronary events in patients with isolated low HDL-cholesterol in a primary prevention setting. The absolute risk reduction in coronary events in the VA-HIT study compares favourably with those reported from the statin-based Cholesterol and Recurrent Events (CARE) and Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) trials. The absolute risk reduction in AFCAPS-TexCAPS is similar to that in West of Scotland Coronary Pravastatin Study (WOSCOPS). Recommendations are given concerning lifestyle and pharmacological management of low HDL-cholesterol. Optimal management also requires review of current treatment targets for HDL-cholesterol and triglycerides levels. |
format | Text |
id | pubmed-59631 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2001 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-596312001-11-06 Treating patients with low high-density lipoprotein cholesterol: choices, issues and opportunities Watts, Gerald F Curr Control Trials Cardiovasc Med Review Three clinical trials have recently focused on the benefits of lipid-regulating therapy in populations with normocholesterolaemia and low high-density lipoprotein (HDL)-cholesterol. Two secondary prevention studies (Veterans Affairs HDL-Cholesterol Intervention Trial [VA-HIT] and Bezafibrate Infarction Prevention [BIP] trial) testified to the efficacy of fibrates in decreasing cardiovascular events, particularly in patients with coexisting risk factors, including hypertriglyceridaemia. The Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) demonstrated that a statin could decrease acute coronary events in patients with isolated low HDL-cholesterol in a primary prevention setting. The absolute risk reduction in coronary events in the VA-HIT study compares favourably with those reported from the statin-based Cholesterol and Recurrent Events (CARE) and Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) trials. The absolute risk reduction in AFCAPS-TexCAPS is similar to that in West of Scotland Coronary Pravastatin Study (WOSCOPS). Recommendations are given concerning lifestyle and pharmacological management of low HDL-cholesterol. Optimal management also requires review of current treatment targets for HDL-cholesterol and triglycerides levels. BioMed Central 2001 2001-05-11 /pmc/articles/PMC59631/ /pubmed/11806784 http://dx.doi.org/10.1186/cvm-2-3-118 Text en Copyright © 2001 Watts; licensee BioMed Central Ltd. Verbatim copying and redistribution of this article are permitted in any medium for any purpose, provided this notice is preserved along with the article's original URL. |
spellingShingle | Review Watts, Gerald F Treating patients with low high-density lipoprotein cholesterol: choices, issues and opportunities |
title | Treating patients with low high-density lipoprotein cholesterol: choices, issues and opportunities |
title_full | Treating patients with low high-density lipoprotein cholesterol: choices, issues and opportunities |
title_fullStr | Treating patients with low high-density lipoprotein cholesterol: choices, issues and opportunities |
title_full_unstemmed | Treating patients with low high-density lipoprotein cholesterol: choices, issues and opportunities |
title_short | Treating patients with low high-density lipoprotein cholesterol: choices, issues and opportunities |
title_sort | treating patients with low high-density lipoprotein cholesterol: choices, issues and opportunities |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC59631/ https://www.ncbi.nlm.nih.gov/pubmed/11806784 http://dx.doi.org/10.1186/cvm-2-3-118 |
work_keys_str_mv | AT wattsgeraldf treatingpatientswithlowhighdensitylipoproteincholesterolchoicesissuesandopportunities |